Avenue

Confidential Computing Market to reach $184.5 Billion, Globally, by 2032 at 46.8% CAGR: Allied Market Research

Retrieved on: 
Friday, September 8, 2023
Health, Software Guard Extensions, AMD, Table, COVID-19, University, Secure, ML, Research, AMR, Privacy, Government, SGX, Chart, Digital technology, ICT, Acquisition, Confidentiality, Intel, AI, BFSI, PDF, Roger Hawkins (drummer), Online shopping, Cryptocurrency, Microsoft Excel, Avenue

PORTLAND, Ore, Sept. 8, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Confidential Computing Market by Component (Hardware, Software, Service), Deployment Mode (On-premise and Cloud), Application (Data Security, Security Enclaves, Pellucidity between Users, and Others), End User (BFSI, IT and Telecom, Healthcare, Retail and E-commerce, Manufacturing, Government and Public Sector, and Others), and Region (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2023-2032." According to the report, the global generated $4.1 billion in 2022, and is estimated to reach $184.5 billion by 2032, witnessing a CAGR of 46.8% from 2023 to 2032.

Key Points: 
  • The COVID-19 pandemic had significantly affected the scale of the confidential computing market.
  • The pandemic had brought to light the dangers and vulnerabilities linked to data breaches and cyberattacks, highlighting the significance of confidential computing for maintaining data security and privacy.
  • The pandemic also had a substantial effect on the confidential computing business in the healthcare sector.
  • The healthcare sector handled very private patient information, such as medical records, identifying information, and research data.

Confidential Computing Market to reach $184.5 Billion, Globally, by 2032 at 46.8% CAGR: Allied Market Research

Retrieved on: 
Friday, September 8, 2023
Health, Software Guard Extensions, AMD, Table, COVID-19, University, Secure, ML, Research, AMR, Privacy, Government, SGX, Chart, Digital technology, ICT, Acquisition, Confidentiality, Intel, AI, BFSI, PDF, Roger Hawkins (drummer), Online shopping, Cryptocurrency, Microsoft Excel, Avenue

PORTLAND, Ore, Sept. 8, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Confidential Computing Market by Component (Hardware, Software, Service), Deployment Mode (On-premise and Cloud), Application (Data Security, Security Enclaves, Pellucidity between Users, and Others), End User (BFSI, IT and Telecom, Healthcare, Retail and E-commerce, Manufacturing, Government and Public Sector, and Others), and Region (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2023-2032." According to the report, the global generated $4.1 billion in 2022, and is estimated to reach $184.5 billion by 2032, witnessing a CAGR of 46.8% from 2023 to 2032.

Key Points: 
  • The COVID-19 pandemic had significantly affected the scale of the confidential computing market.
  • The pandemic had brought to light the dangers and vulnerabilities linked to data breaches and cyberattacks, highlighting the significance of confidential computing for maintaining data security and privacy.
  • The pandemic also had a substantial effect on the confidential computing business in the healthcare sector.
  • The healthcare sector handled very private patient information, such as medical records, identifying information, and research data.

AVENUE OF THE ARTS INC. CELEBRATES MILESTONE 30TH ANNIVERSARY FRIDAY, OCTOBER 6 AT THE W PHILADELPHIA WITH MUSICAL PERFORMANCES AND A SNEAK PEEK AT ITS EXCITING PLANS FOR THE FUTURE

Retrieved on: 
Wednesday, September 6, 2023
Stylistics, Suzanne Roberts Theatre, Kimmel Center for the Performing Arts, The arts, University, The Stylistics, Gensler, Performing arts, Friends, Marketing, Culture, Eye, Wilma Theater, Multimedia, Opera Philadelphia, Washington Avenue, Brandywine Workshop and Archives, Pulitzer, City, Pulitzer Prize, Work, Creative, Secondary school, Prince, Economic development, Ijames, Broadway, AAI, Fat Ham, Town hall, Hamlet, Jazz, Nightclub, Interior design, Avenue

PHILADELPHIA, Sept. 6, 2023 /PRNewswire/ -- Avenue of the Arts, Inc. (AAI), the nonprofit organization that is both an advocate and economic development catalyst for Philadelphia's cultural and performing arts district, will celebrate its 30th anniversary Friday, October 6th, 6:30 to 9:30 p.m.at the W Philadelphia hotel in Center City.

Key Points: 
  • The AAI Visionary Award is given annually to those who have shown extraordinary accomplishment and leadership in the performing arts in Philadelphia.
  • "I look forward to celebrating the Avenue with so many of my friends in the Philly arts community."
  • The Avenue of the Arts, Inc. is excited to present a sneak peek at its plans for the future of the Avenue at the Anniversary Gala.
  • We want to make sure that the arts community continues to not just entertain but support the Philadelphia economy in the future."

Avenue Z Continues Rapid Expansion Marking Third Acquisition in 2023

Retrieved on: 
Wednesday, September 6, 2023
Social Media, Other Communications, Search Engine Marketing, Blogging, Public Relations, Investor Relations, Marketing, Advertising, Communications, SEO, Hughes, The Walt Disney Company, AI, Acquisition, Human, Avenue, Content, Universal Pictures

The Avenue Z Network , a strategic communications and marketing advisory, today announced the acquisition of a leading digital marketing and SEO company, Designzillas .

Key Points: 
  • The Avenue Z Network , a strategic communications and marketing advisory, today announced the acquisition of a leading digital marketing and SEO company, Designzillas .
  • Marking its third acquisition this year, Avenue Z is acquiring specialized marketing firms at a rapid pace and plans to rebrand Designzillas to Avenue Z by the end of the year.
  • Avenue Z CEO Jeffrey Herzog has a vision for the convergence of influence across public relations and digital marketing: “We have developed integrated, data-driven strategies that increase market share and share of voice for our clients,” said Herzog.
  • Following the acquisition, Avenue Z plans to move into new office facilities in the downtown Orlando area with space for 100 employees.

Wyndham Hotels & Resorts Surpasses 100 Open Hotels in Türkiye

Retrieved on: 
Tuesday, September 5, 2023
Galata Tower, Heart, Collection, Istanbul Cevahir, Travel, Hagia Sophia, Days Inn, Sufism, Basilica Cistern, Afyonkarahisar Castle, Grand Bazaar, Topkapı Palace, Republic, Hammam, Restaurant, Mall, Avenue, Bath, Istanbul Airport, City, Blue Mosque, Health, Wyndham Hotels & Resorts, Hotel, Tourism, Central Anatolia Region, Golden Horn

ISTANBUL, Sept. 5, 2023 /PRNewswire/ -- Wyndham Hotels & Resorts, the world's largest hotel franchising company with approximately 9,100 hotels spanning more than 95 countries, is further strengthening its position in Türkiye reaching approximately 105 open and operating hotels and a development pipeline of approximately 20 additional properties. The latest openings are part of Wyndham's continued expansion plan in Türkiye, where the company is the largest international hotel group by number of properties.

Key Points: 
  • ISTANBUL, Sept. 5, 2023 /PRNewswire/ -- Wyndham Hotels & Resorts, the world's largest hotel franchising company with approximately 9,100 hotels spanning more than 95 countries, is further strengthening its position in Türkiye reaching approximately 105 open and operating hotels and a development pipeline of approximately 20 additional properties.
  • Dimitris Manikis, President EMEA, Wyndham Hotels & Resorts, said: "From culture-rich destinations to beautiful coastlines and buzzing cities, Türkiye has something to offer to every type of traveller.
  • Wyndham continues delivering on its mission of making hotel travel possible for all, recently opening several new hotels across Türkiye.
  • Wyndham hotels in Türkiye participate in Wyndham Rewards®, the award-winning hotel loyalty programme offering over 103 million enrolled members the opportunity to redeem points at thousands of hotels, vacation club resorts and vacation rentals globally.

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, August 10, 2023
Epilepsy, DSM-IV codes, Seizure, Spinal and bulbar muscular atrophy, IV, Symantec Endpoint Protection, PO, Anterior grey column, Schedule, SBMA, Pain, U.S. FDA, Morphine, Patient, Hydromorphone, Research, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tramadol, Food, Safety, Generalized tonic–clonic seizure, D, Pharmaceutical industry, Avenue

MIAMI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the second quarter ended June 30, 2023.

Key Points: 
  • Additionally, we reported promising preclinical results for BAER-101 that show robust anti-seizure activity in a translational animal model of absence epilepsy.
  • R&D Expenses: Research and development expenses for the second quarter of 2023 were $3.0 million, compared to $0.2 million for the second quarter of 2022.
  • G&A Expenses: General and administrative expenses for the second quarter of 2023 were $0.9 million, compared to $0.5 million for the second quarter of 2022.
  • Net Loss: Net loss attributable to common stockholders for the second quarter of 2023 was $4.0 million, or $0.52 per share, compared to a net loss of $0.6 million, or $0.41 per share, for the second quarter of 2022.

REEP Equity Releases Comprehensive Guide to Multifamily Real Estate Investing

Retrieved on: 
Wednesday, August 9, 2023
Avenue, Entrepreneurship, Research, Investment, Benefit, SAN

SAN ANTONIO, Aug. 9, 2023 /PRNewswire/ -- The world of investment offers an array of opportunities, ranging from traditional stocks and bonds to the ever-evolving world of cryptocurrencies and commodities. One particularly promising avenue is multifamily real estate investments in the United States. However, like any investment venture, it comes with inherent risks that necessitate thorough research and understanding before making any decisions.

Key Points: 
  • One particularly promising avenue is multifamily real estate investments in the United States.
  • REEP Equity , a leading multifamily real estate firm with its own in-house management company, recognizes the significance of having a reliable and compatible investment partner.
  • To assist investors in navigating the process and making informed decisions, REEP Equity has released a free comprehensive guide titled " Your Guide to Multifamily Investing: Unlock the Benefits & Discover How to Select the Right Investment Partner ."
  • Choosing the right investment partner is crucial to achieving success," said Jacob Garza, Co-Founder of REEP Equity.

Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study

Retrieved on: 
Tuesday, August 1, 2023
Epilepsy, DSM-IV codes, Seizure, Generalized tonic–clonic seizure, Human, Deficit spending, PO, Ataxia, AstraZeneca, Eli Lilly, Patient, GAERS, Addiction, Therapy, FAAN, Safety, Pharmaceutical industry, Avenue

The GAERS model mimics behavioral, electrophysiological and pharmacological features of human absence seizures.

Key Points: 
  • The GAERS model mimics behavioral, electrophysiological and pharmacological features of human absence seizures.
  • The GAERS model is a proven, early, informative indicator of efficacy in anti-seizure drug development, with high predictability of response in humans.
  • In the model, BAER-101 demonstrated full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg, PO.
  • The combination of safety, tolerability and efficacy in an established translationally relevant epilepsy model support BAER-101’s continued development.

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Retrieved on: 
Thursday, July 27, 2023
DSM-IV codes, Spinal and bulbar muscular atrophy, Neurodegenerative disease, Clinical trial, Biomarker, Anterior grey column, SBMA, MRI, NRF1, Oxidative stress, Patient, NFE2L2, Therapy, AR, Safety, Pharmaceutical industry, Medical imaging, Avenue

MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that the first patient has been dosed in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease.

Key Points: 
  • MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that the first patient has been dosed in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease.
  • “We are excited to announce that the first patient has been dosed in our Phase 1b/2a clinical trial evaluating AJ201 for the treatment of SBMA, a progressive and devastating neurodegenerative disease that currently has no approved treatments available,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • “We are encouraged by the Phase 1 clinical data of AJ201 that demonstrate the drug’s excellent safety profile in healthy volunteers.
  • The primary endpoint of the study is to assess safety and tolerability of AJ201 in subjects with clinically and genetically defined SBMA.

Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol

Retrieved on: 
Tuesday, July 25, 2023
Epilepsy, DSM-IV codes, Partnership, IV, Element, Schedule, Pain, Morphine, Patient, Physician, Hypoventilation, Norepinephrine, Hydromorphone, Serotonin, FDA, Therapy, Tramadol, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Avenue

The agreed upon non-inferiority study is designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.

Key Points: 
  • The agreed upon non-inferiority study is designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.
  • The study will randomize post bunionectomy patients to IV tramadol or IV morphine for pain relief administered during a 48-hour post-operative period.
  • Of note, IV tramadol demonstrated safety and efficacy in this same surgical model in a Phase 3 efficacy trial.
  • We remain committed to Avenue’s mission of delivering impactful therapies to treat patients with neurologic diseases, while building shareholder value,” said Dr. MacLean.